Making Sense of the Destination as the Operational Discipline Around Follow-Up Periods After Mammography

Federal Mammography Quality Standards Act (MQSA) rules require specific assessment statements in every mammography report. These statements are mandatory. American College of Radiology (ACR) BI-RADS® numeric categories and associated management language form a widely used professional mapping to those statements, yet the numeric codes themselves are not required by the U.S. Food and Drug Administration (FDA).^1,2 Interpreting physicians frequently issue mixed or customized recommendations. Therefore the only reliable driver of patient tracking and navigation is the actual written recommendation that appears in the report. Assessment category and stated recommendation must be validated against each other in every case. No exceptions.

FDA MQSA Mandated Assessment Statements Come First

Under 21 CFR 900.12(c)(1), every mammography report must contain an overall final assessment of findings expressed as one of the following exact (or FDA-accepted equivalent) statements: "Negative," "Benign," "Probably Benign," "Suspicious," "Highly Suggestive of Malignancy," "Known Biopsy-Proven Malignancy," or "Post-Procedure Mammogram for Marker Placement."¹ When no final assessment can be rendered, the report must state either "Incomplete: Need additional imaging evaluation" or "Incomplete: Need prior mammograms for comparison." The reasons for incompleteness must also be documented.^1,2

FDA regulations require only these textual assessment statements. Addition of an ACR BI-RADS® numeric code (0 through 6) is permitted but is not mandatory and does not satisfy the federal requirement by itself.^2,3 The management recommendation that accompanies the assessment statement is the operational instruction that must be followed. In real-world practice that recommendation often matches the conventional pathway associated with the assessment, yet it is not guaranteed to do so. Physicians may recommend biopsy for a "Probably Benign" finding, short-interval imaging for a "Suspicious" finding under specific clinical circumstances, or additional clinical consultation alongside any category. Tracking and navigation systems must therefore read both the mandated assessment statement and the free-text or structured recommendation that follows it, then act on the recommendation as written.

Incomplete Assessments: Immediate Action to Complete the Study

An assessment of "Incomplete: Need additional imaging evaluation" or "Incomplete: Need prior mammograms for comparison" indicates that the examination cannot yet receive a final assessment. The corresponding ACR BI-RADS® mapping is Category 0.³ The stated recommendation will almost always call for prompt additional mammographic views, ultrasound, or retrieval of prior examinations. That recommendation must be executed without delay. Facilities must schedule the additional imaging or obtain the priors and issue a new report containing one of the final assessment statements listed above. When the assessment is "Incomplete: Need prior mammograms for comparison," a final assessment report is required within 30 calendar days whether or not the priors are obtained.^1,2

Any tracking process that treats every incomplete examination as a generic "recall" without confirming the precise recommendation text risks leaving studies open indefinitely. Validation of the written recommendation is the only safe procedure.

"Probably Benign": Short-Interval Surveillance When Recommended

The MQSA assessment statement "Probably Benign" indicates that the finding(s) have a high probability of being benign. The conventional ACR BI-RADS® mapping is Category 3, which carries an expected likelihood of malignancy greater than 0 percent but less than or equal to 2 percent after complete diagnostic evaluation.^3,4

When the report recommends short-interval follow-up, the usual interval is six months for the affected breast or breasts, followed by continued surveillance imaging (commonly another six-month examination and then annual imaging until 24 months of documented stability). Once long-term stability is confirmed, the finding is typically reclassified under a "Benign" assessment and the patient returns to routine screening.^3,4

Large observational data demonstrate that this pathway is safe when the recommendation is followed. In the National Mammography Database analysis of more than 43,000 women who received a Category 3 assessment after screening recall and accepted surveillance, cumulative cancer yield through two years was 1.86 percent. Of the 810 malignancies diagnosed, 57.8 percent were identified at or before the six-month examination.⁵ The foundational prospective series by Sickles demonstrated a cancer yield of 0.5 percent among 3,184 consecutive probably benign lesions managed with periodic mammographic surveillance; nearly all cancers were detected by interval change while still Stage 0 or I.⁶

These figures apply only when the written recommendation is short-interval surveillance. If the interpreting physician instead recommends biopsy, clinical consultation, or a different interval, the stated recommendation governs. Tracking systems that assume every "Probably Benign" assessment automatically receives a six-month mammogram will mismanage a non-trivial fraction of cases.

"Suspicious" and "Highly Suggestive of Malignancy": Tissue Diagnosis When Recommended

The MQSA statements "Suspicious" and "Highly Suggestive of Malignancy" indicate definite or high probability of malignancy. The conventional ACR BI-RADS® mappings are Category 4 (with optional subcategories 4A, 4B, 4C) and Category 5, respectively.³ The usual recommendation is tissue diagnosis, preferably image-guided core-needle biopsy. When that recommendation is present, prompt coordination of biopsy is required. FDA also imposes a seven-calendar-day deadline for delivery of the report and patient lay summary when either of these assessments is used.²

Again, the written recommendation is authoritative. A report may state "Suspicious" yet recommend short-interval imaging under unusual clinical circumstances, or it may recommend surgical consultation in addition to biopsy. Navigation must follow the text that appears, not the textbook pathway associated with the assessment label.

Other Assessments and Accompanying Recommendations

"Negative" and "Benign" assessments ordinarily return the patient to routine age-appropriate screening. "Known Biopsy-Proven Malignancy" and "Post-Procedure Mammogram for Marker Placement" carry their own clinical contexts and usually direct the patient toward ongoing oncologic or procedural care.¹ Any assessment statement may be accompanied by additional recommendations that fall outside the core imaging pathway: consultation with a breast surgeon, supplemental breast magnetic resonance imaging for dense breasts or elevated risk, or clinical follow-up of a palpable finding. These statements must be captured and acted upon with the same rigor applied to the primary recommendation.

Operational Protocol for Tracking and Navigation

The system that determines patient outcome is the closed-loop execution of the recommendation actually written in the report. The assessment category provides useful context and supports auditing, yet it is secondary. The protocol is therefore:

1. Extract the exact MQSA assessment statement.
2. Extract the stated management recommendation (imaging interval, biopsy, consultation, or other).
3. Validate that the two are coherent; if they conflict or if the recommendation is ambiguous, escalate for clarification before acting.
4. Schedule and track the recommended action according to its explicit time target.
5. Confirm completion and issue or receive the subsequent report.

Facilities that treat the assessment label as a reliable proxy for the recommendation will generate both over- and under-action. Facilities that read the recommendation first and treat the assessment as supporting context will close incomplete studies, monitor true probably-benign findings, and accelerate tissue diagnosis when it is ordered.

Leadership question: Does every tracking and navigation workflow in your organization begin by reading the free-text or structured recommendation that follows the MQSA assessment statement, or does it still default to an assumed pathway derived solely from the assessment label or BI-RADS® code?

---

About the Author

Richard D. Lippert Jr. is the founder of Mammologix and has supported breast imaging centers with patient follow-up tracking, lay communication, compliance documentation, and operational strategy since 1995.

References

1. U.S. Food and Drug Administration. 21 CFR 900.12 Quality standards. Current as of 2024 amendments effective September 10, 2024. ecfr.gov/current/title-21/section-900.12

2. U.S. Food and Drug Administration. Important Information: Final Rule to Amend the Mammography Quality Standards Act (MQSA). fda.gov/radiation-emitting-products/mqsa-final-rule

3. American College of Radiology. ACR BI-RADS® Atlas, 5th Edition (2013) and BI-RADS® v2025 Manual. Reston, VA: American College of Radiology. acr.org

4. American College of Radiology. ACR BI-RADS® Mammography Frequently Asked Questions (updated September 10, 2024). acr.org

5. Berg WA, et al. Cancer Yield and Patterns of Follow-up for BI-RADS Category 3 after Screening Mammography Recall in the National Mammography Database. Radiology. 2020;296(1):32-41. doi:10.1148/radiol.2020191508

6. Sickles EA. Periodic mammographic follow-up of probably benign lesions: results in 3,184 consecutive cases. Radiology. 1991;179(2):463-468. doi:10.1148/radiology.179.2.2014293

7. Lee CS, et al. Understanding BI-RADS Category 3. RadioGraphics. 2025;45(1). doi:10.1148/rg.240169